Earkart Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹7 Cr
QMarch 2025
In 2026, Earkart (EARKART) reported revenue ₹0 Cr and net profit ₹0 Cr. For annual financials, live price and key ratios, visit EARKART screener.
EARKART Quarterly Results — Revenue, Profit & EPS Highlights
Earkart latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore EARKART share price charts to track price trends across different timeframes.
- Revenue of ₹43 Cr in March 2025 (+0.0% vs March 2025, +34.4% vs March 2024)
- Net Profit of ₹7 Cr in March 2025 (+0.0% vs March 2025, +133.3% vs March 2024)
- EBITDA of ₹10 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 23.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹6.59 in March 2025 (+0.0% vs March 2025)
Earkart Quarterly Results — Revenue, EBITDA, Net Profit & EPS
EARKART quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 0 | 43 | 32 | 29 | 6 | - | - |
| Net Profit (₹ Cr) | 0 | 7 | 3 | 1 | 0 | - | - |
| EBITDA (₹ Cr) | 0 | 10 | 4 | 2 | 0 | - | - |
| EPS (₹) | 0.00 | 6.59 | 2.03 | 0.87 | 20.15 | - | - |
| Operating Margin (%) | 0.0% | 23.0% | 11.0% | 6.0% | 2.0% | - | - |
EARKART Share Price Trend — 1-Year Movement Across Quarterly Results
Earkart 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with EARKART stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
March 2023
29
March 2024
32
March 2025
43
2026
0
Net Profit Trend (₹ Cr)
March 2023
1
March 2024
3
March 2025
7
2026
0
Operating Margin Trend (%)
March 2023
6.0%
March 2024
11.0%
March 2025
23.0%
2026
0.0%
EARKART vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Earkart latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1878.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6760.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.3 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹149,048.00 Cr | 4405.7 | 3,219 | 591 | +11.3% | - | 18.4% | 251.2 |
|
Cipla
Mar 2026 |
₹116,053.85 Cr | 1432.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 208.5 |
|
Dr Reddys Laborator…
Mar 2026 |
₹108,804.06 Cr | 1336.7 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 504.4 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores